رجوع

Aurinia Pharmaceuticals Inc.

جودة البيانات: 100%

AUPH

NASDAQ Healthcare Biotechnology

KWD 14.56

▲ KWD 0.54 (3.85%)

القيمة السوقية: 1.94B

نطاق اليوم

KWD 14.40 KWD 15.22

نطاق 52 أسبوعًا

KWD 6.83 KWD 16.54

حجم التداول

2,370,754

متوسط 50 يوم / 200 يوم

KWD 14.57 / KWD 12.72

الإغلاق السابق

KWD 14.02

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس	السهم	وسيط القطاع
P/E	6.7	0.4
P/B	3.3	2.9
ROE %	59.9	3.8
Net Margin %	101.5	3.9
Rev Growth 5Y %	57.8	10.0
D/E	0.1	0.2

السعر المستهدف للمحللين

Hold

KWD 15.500 +6.5%

Low: KWD 15.000 High: KWD 16.000

مكرر الربحية المستقبلي

17.9

ربحية السهم المستقبلية

KWD 0.813

نمو ربحية السهم (تقدير)

+0.0%

الإيرادات المقدّرة

330 M

تقديرات الأرباح

الفترة	تقدير ربحية السهم	تقدير الإيرادات	المحللون
FY2030	KWD 1.643 KWD 1.561 – KWD 1.842	520 M	2
FY2029	KWD 1.257 KWD 1.194 – KWD 1.408	470 M	2
FY2028	KWD 1.270 KWD 0.432 – KWD 2.118	440 M	4

النقاط الرئيسية

Revenue grew 57.84% annually over 5 years — strong growth

Earnings grew 4893.08% over the past year

ROE of 59.91% indicates high profitability

Net margin of 101.47% shows strong profitability

Debt/Equity of 0.13 — conservative balance sheet

Generating 135.41M in free cash flow

النمو

Revenue Growth (5Y)

57.84%

Revenue (1Y)20.38%

Earnings (1Y)4893.08%

FCF Growth (3Y)N/A

الجودة

Return on Equity

59.91%

ROIC11.99%

Net Margin101.47%

Op. Margin37.06%

الأمان

Debt / Equity

0.13

Current Ratio5.25

Interest Coverage24.23

التقييم

P/E Ratio

6.74

P/B Ratio3.33

EV/EBITDA18.40

Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	20.38%	Revenue Growth (3Y)	26.99%
Earnings Growth (1Y)	4893.08%	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	57.84%	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	283.06M	Net Income (TTM)	287.20M
ROE	59.91%	ROA	38.21%
Gross Margin	88.46%	Operating Margin	37.06%
Net Margin	101.47%	Free Cash Flow (TTM)	135.41M
ROIC	11.99%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	0.13	Current Ratio	5.25
Interest Coverage	24.23	Dividend Yield	0.00%
Valuation
P/E Ratio	6.74	P/B Ratio	3.33
P/S Ratio	6.84	PEG Ratio	0.00
EV/EBITDA	18.40	Dividend Yield	0.00%
Market Cap	1.94B	Enterprise Value	1.93B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	283.06M	235.13M	175.51M	134.03M	45.61M
Net Income	287.20M	5.75M	-78.02M	-108.18M	-180.97M
EPS (Diluted)	2.07	0.04	-0.54	-0.76	-1.40
Gross Profit	250.39M	206.89M	161.37M	128.37M	44.51M
Operating Income	104.91M	-4.69M	-91.69M	-111.47M	-180.74M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	751.59M	550.65M	548.06M	470.86M	543.37M
Total Liabilities	170.26M	173.17M	170.11M	65.43M	64.28M
Shareholders' Equity	581.33M	377.48M	377.95M	405.44M	479.09M
Total Debt	74.81M	79.37M	97.61M	8.09M	8.74M
Cash & Equivalents	80.21M	83.43M	48.88M	94.17M	231.90M
Current Assets	491.97M	446.60M	424.80M	442.54M	513.32M
Current Liabilities	93.72M	97.76M	77.19M	46.11M	40.65M

درجات الاستراتيجيات

This stock passed the criteria for 6 strategies

Score = fit strength (0–100)

Rank = position among all matches

Custom Capital Light Compounder

#53 of 213

Custom Contrarian Investing (David Dreman)

#9 of 658

Growth Growth Investing (Philip Fisher)

#30 of 154

Custom Full Throttle

#126 of 146

Value Value Investing (Warren Buffett)

#6 of 195

Custom Lower Risk

#39 of 136

النشاط الأخير

دخل Capital Light Compounder

Mar 24, 2026

دخل Contrarian Investing (David Dreman)

Mar 24, 2026

دخل Growth Investing (Philip Fisher)

Mar 24, 2026

دخل Value Investing (Warren Buffett)

Mar 24, 2026

دخل Full Throttle

Mar 24, 2026

دخل Lower Risk

Mar 24, 2026